Opinion|Videos|July 15, 2024
Atopic Dermatitis Treatment Advances and Changing Quality of Life Expectations
Author(s)Shawn Kwatra, MD
An expert on atopic dermatitis provides insights on how the evolving treatment landscape has impacted clinician and patient expectations.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- With the expansion of treatment options for atopic dermatitis (AD) in recent years, how have clinician and patient expectations changed regarding treatments and QoL improvements?
- What recommendations do you have to manage patient expectations and discuss AD treatment goals with patients?
Advertisement
Related to this article
KT-621, an oral STAT6 degrader, cut mean EASI by 62.6% after 4 weeks with no treatment-related adverse events in a phase 1b atopic dermatitis study.
Phase 2 and 3 data show difamilast 1% ointment improved severity and itch within 1 week in adults and children with mild to moderate atopic dermatitis.
Advertisement
Advertisement
Trending on HCPLive
1
2027 GOLD Report Update Preview: Changes in COPD Treatment, Biologics
2
Noninvasive Models Underestimate CSPH in MASH Cirrhosis vs HVPG
3
Lp(a) HORIZON Shows Pelacarsen Lowers Lp(a) 78% But Not Cardiovascular Events
4
Once-Monthly Efimosfermin Improves Fibrosis Markers in Phase 2 MASH Study
5